People & Business :: Companies
Biotech: Lonza Ties with Cellectis to Improve Cell Lines
1:28 PM MDT | June 8, 2010 | Alex Scott
Lonza says it has agreed a deal with Cellectis (Paris; France), a biotech firm involved in genome customization, to develop and commercialize bioengineered cell lines for manufacturing biologic drugs. Under the deal, Cellectis will use meganucleases, which act as molecular scissors to modify Lonza’s cell lines. Meganucleases can be directed to a single, highly specific site in the genome of a cell, thereby allowing a wide range of precise genome modifications, including targeted gene integration, gene knock-out as well as modulation of gene...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee